Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week Low - Here's What Happened

Key Points

• Syndax shares hit a 52-week low of $12.69, down from the prior close of $14.29.
• Third-quarter revenue rose 82% year over year to $83.3 million, beating estimates, but the company’s $0.55-per-share loss was wider than the $0.50 consensus estimate.
• The company announced 19 accepted ASH 2026 abstracts for Revuforj and Niktimvo, while pipeline setbacks and an announced investor-law-firm investigation add uncertainty for shareholders.

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) reached a new 52-week low on Wednesday. The company traded as low as $12.69 and last traded at $12.72, with a volume of 1,656,243 shares. The stock had previously closed at $14.29.

Trending Headlines about Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Syndax said 19 abstracts covering Revuforj (revumenib) and Niktimvo (axatilimab-csfr) were accepted for ASH 2026, including seven oral presentations. Revumenib data span several acute leukemia settings, while axatilimab abstracts include longer-term data in chronic graft-versus-host disease. The breadth of presentations may support investor confidence in the therapies’ potential. ASH abstracts announcement
• Positive Sentiment: Third-quarter revenue rose 82% year over year to $83.3 million, above analyst estimates. Revuforj revenue increased 90% to $60.7 million, with new patients up 20% sequentially; Niktimvo partner sales were $67.4 million, generating $22.6 million in Syndax collaboration revenue. Third-quarter results and business update
• Neutral Sentiment: Syndax appointed Aaron A. Ondrey CFO effective November 9. Current CFO Keith Goldan plans to retire but will remain through year-end to support the transition, indicating a planned handover. CFO transition announcement
• Neutral Sentiment: The company will hold an investor event during the ASH meeting on December 14, providing an opportunity to discuss its therapies and data, but no new results were announced with the event notice. ASH investor event announcement
• Negative Sentiment: Syndax’s quarterly loss of $0.55 per share was wider than the roughly $0.50 consensus estimate, despite the revenue beat and improvement from a year-earlier loss. Reports also cite pipeline setbacks as an overhang, tempering the commercial growth story. Earnings and pipeline concerns
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Syndax investors. The notice provides no specific findings, but adds legal uncertainty and headline risk. Investor investigation notice

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Weiss Ratings raised Syndax Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday. UBS Group reaffirmed a "buy" rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Jefferies Financial Group reiterated a "buy" rating and set a $35.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. HC Wainwright cut their price objective on Syndax Pharmaceuticals from $38.00 to $36.00 and set a "buy" rating for the company in a report on Tuesday. Finally, JPMorgan Chase & Co. reduced their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $41.60.

Syndax Pharmaceuticals Stock Down 26.0%

The stock's 50-day moving average price is $16.95 and its 200-day moving average price is $20.18. The company has a current ratio of 6.77, a quick ratio of 6.44 and a debt-to-equity ratio of 38.95. The stock has a market cap of $936.61 million, a price-to-earnings ratio of -4.48 and a beta of 0.48.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The company had revenue of $83.30 million during the quarter, compared to the consensus estimate of $81.38 million. Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 517.88%. The company's revenue for the quarter was up 81.9% on a year-over-year basis. During the same period last year, the firm posted ($0.70) earnings per share. On average, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -2.03 earnings per share for the current year.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 8,000 shares of the firm's stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $14.21, for a total value of $113,680.00. Following the completion of the sale, the director owned 239,763 shares of the company's stock, valued at $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allworth Financial LP acquired a new position in Syndax Pharmaceuticals in the second quarter valued at about $26,000. Sterling Capital Management LLC lifted its position in shares of Syndax Pharmaceuticals by 846.6% during the 3rd quarter. Sterling Capital Management LLC now owns 2,963 shares of the company's stock worth $56,000 after buying an additional 2,650 shares during the last quarter. Nykredit A S acquired a new stake in shares of Syndax Pharmaceuticals during the second quarter worth about $72,000. Integrated Wealth Concepts LLC purchased a new stake in Syndax Pharmaceuticals in the second quarter valued at approximately $73,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter worth $86,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc NASDAQ: SNDX is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax's lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.